Risks and complications of transurethral resection of bladder tumor among patients taking antiplatelet agents for cardiovascular disease

Stefano Picozzi, Carlo Marenghi, Cristian Ricci, Giorgio Bozzini, Stefano Casellato, Luca Carmignani

Research output: Contribution to journalArticle

Abstract

Background Urologists have not reached a consensus regarding the pre-, intra-, and postoperative management of patients taking antiplatelet agents. This study aimed to evaluate the clinical course of patients receiving antithrombotic monotherapy with acetylsalicylic acid (ASA) 100 mg who underwent transurethral resection of bladder cancer. Methods This study was designed to compare the surgical outcomes for 108 transurethral resections of bladder cancer performed for patients taking antiplatelet therapy and for 105 procedures performed for patients who had never taken antiplatelet agents before surgery. Antiaggregant therapy was maintained according to criteria evaluated by a urologist, surgeon, anesthesiologist, and cardiologist. Variables were described using the mean as the location index and using standard deviation as a dispersion index if continuous percentages were used elsewhere. Group comparisons were performed using the t test or the chi-square test for categorical data, and Fisher's exact test was used where appropriate. Results The mean operative time for patients taking ASA was 31 min (range 10-65 min), whereas it was 26 min (range 5-60 min) for control subjects. The difference between pre- and postoperative hemoglobin values was -0.6 g/dl in the group receiving antiplatelet therapy and -0.8 g/dl in the control group (p = 0.0720). Transfusional support was required during four procedures performed for patients taking antiplatelet therapy and during two procedures for the control group (p = 0.242). No adverse cardiac events or anesthesia-related complications occurred. Three patients in the treatment group and two patients in the control group required reintervention to ensure hemostasis during the postoperative period. None of the patients in either group underwent rehospitalization for hematuria after leaving the hospital. Conclusion The current results suggest that continued use of anti-aggregant monotherapy does not increase the risk of overall bleeding or reintervention for patients undergoing transurethral resection of bladder neoplasms and that suspending aspirin before such a procedure is therefore unnecessary.

Original languageEnglish
Pages (from-to)116-121
Number of pages6
JournalSurgical Endoscopy and Other Interventional Techniques
Volume28
Issue number1
DOIs
Publication statusPublished - Jan 2014

Keywords

  • Antiaggregant
  • Antiplatelets
  • Bladder
  • Cancer
  • Transurethral resection
  • TURBT

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Risks and complications of transurethral resection of bladder tumor among patients taking antiplatelet agents for cardiovascular disease'. Together they form a unique fingerprint.

  • Cite this